Claus Christian Pieper1, Winfried A Willinek2, Daniel Thomas2, Hojjat Ahmadzadehfar3, Markus Essler3, Jennifer Nadal4, Kai E Wilhelm2, Hans Heinz Schild2, Carsten Meyer2. 1. Department of Radiology, University of Bonn, Sigmund-Freud-Str. 25, 53105, Bonn, Germany. claus.christian.pieper@ukb.uni-bonn.de. 2. Department of Radiology, University of Bonn, Sigmund-Freud-Str. 25, 53105, Bonn, Germany. 3. Department of Nuclear Medicine, University of Bonn, Sigmund-Freud-Str. 25, 53105, Bonn, Germany. 4. Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, Sigmund-Freud-Strasse 25, 53105, Bonn, Germany.
Abstract
OBJECTIVES: To retrospectively determine incidence of early arterial blood flow stasis and its influencing factors during resin-based radioembolization (RE) of liver tumours. METHODS: Data of patients undergoing resin-based RE from 06/2006-12/2013 were reviewed. Second RE procedures of the same liver lobe were excluded. 90-yttrium dose was calculated according to the body surface area method. Data were categorized according to RE without full dose application because of early stasis and with full dose application. Clinical/procedural characteristics were recorded. Logistic regression was performed to identify associations between clinical/procedural characteristics and early stasis. RESULTS: 362 patients [220 male; mean age 62 years (range 26-90)] underwent 416 RE sessions with early stasis occurring in 103 REs (24.8 %). Highest incidence and degree of stasis were observed in breast cancer metastases [42.6 % (20/47); 55.8 % of mean intended dose administered]. Independent risk factors were: metastasized breast cancer (odds ratio [OR] 2.18, p = 0.02), liver tumour-burden <25 % and 25-50 % (ORs 5.33, 15.64; p < 0.0001), tumour hypovascularity (OR 2.70, p = 0.04), previous bevacizumab therapy (OR 2.79, p = 0.0009) and concurrent chemotherapy (OR 8.69, p < 0.0001). CONCLUSION: Early stasis was observed in 24.8 % of resin-based REs. In the presence of the identified risk factors, extra care should be taken during microsphere administration. KEY POINTS: • Early arterial blood flow stasis is a known problem of resin-based RE. • The study showed that early stasis occurs in 25 % of REs. • Several clinical and procedural factors are associated with early stasis. • In patients at risk extra care should be taken during RE.
OBJECTIVES: To retrospectively determine incidence of early arterial blood flow stasis and its influencing factors during resin-based radioembolization (RE) of liver tumours. METHODS: Data of patients undergoing resin-based RE from 06/2006-12/2013 were reviewed. Second RE procedures of the same liver lobe were excluded. 90-yttrium dose was calculated according to the body surface area method. Data were categorized according to RE without full dose application because of early stasis and with full dose application. Clinical/procedural characteristics were recorded. Logistic regression was performed to identify associations between clinical/procedural characteristics and early stasis. RESULTS: 362 patients [220 male; mean age 62 years (range 26-90)] underwent 416 RE sessions with early stasis occurring in 103 REs (24.8 %). Highest incidence and degree of stasis were observed in breast cancer metastases [42.6 % (20/47); 55.8 % of mean intended dose administered]. Independent risk factors were: metastasized breast cancer (odds ratio [OR] 2.18, p = 0.02), liver tumour-burden <25 % and 25-50 % (ORs 5.33, 15.64; p < 0.0001), tumour hypovascularity (OR 2.70, p = 0.04), previous bevacizumab therapy (OR 2.79, p = 0.0009) and concurrent chemotherapy (OR 8.69, p < 0.0001). CONCLUSION: Early stasis was observed in 24.8 % of resin-based REs. In the presence of the identified risk factors, extra care should be taken during microsphere administration. KEY POINTS: • Early arterial blood flow stasis is a known problem of resin-based RE. • The study showed that early stasis occurs in 25 % of REs. • Several clinical and procedural factors are associated with early stasis. • In patients at risk extra care should be taken during RE.
Authors: N Sogo; I B Wilkinson; H MacCallum; S Q Khan; F E Strachan; D E Newby; I L Megson; D J Webb Journal: Clin Pharmacol Ther Date: 2000-07 Impact factor: 6.875
Authors: Andreas H Mahnken; Carlo Spreafico; Geert Maleux; Thomas Helmberger; Tobias F Jakobs Journal: Cardiovasc Intervent Radiol Date: 2013-03-20 Impact factor: 2.740
Authors: Ravi Murthy; Henry Xiong; Rodolfo Nunez; Alan C Cohen; Bruce Barron; Janio Szklaruk; David C Madoff; Sanjay Gupta; Michael J Wallace; Kamran Ahrar; Marshall E Hicks Journal: J Vasc Interv Radiol Date: 2005-07 Impact factor: 3.464
Authors: Ravi Murthy; Rodolfo Nunez; Janio Szklaruk; William Erwin; David C Madoff; Sanjay Gupta; Kamran Ahrar; Michael J Wallace; Alan Cohen; Douglas M Coldwell; Andrew S Kennedy; Marshall E Hicks Journal: Radiographics Date: 2005-10 Impact factor: 5.333
Authors: Peachy Mae Piana; Voichita Bar; Laura Doyle; Rani Anne; Takami Sato; David J Eschelman; Jeffrey W McCann; Carin F Gonsalves; Daniel B Brown Journal: HPB (Oxford) Date: 2013-06-19 Impact factor: 3.647
Authors: Carsten Meyer; Claus Christian Pieper; Hojjat Ahmadzadehfar; Nina Alexandra Lampe; Eva Maria E Matuschek; Thomas Adrian Maschke; Simon Jonas Enkirch; Markus Essler; Ulrich Spengler; Hans Heinz Schild Journal: Onco Targets Ther Date: 2017-09-26 Impact factor: 4.147
Authors: Brigitte Maximiliana Aarts; Elisabeth Geneviève Klompenhouwer; Raphaëla Carmen Dresen; Christophe Michel Albert Louis Omer Deroose; Regina Gien Hoa Beets-Tan; Kevin Punie; Patrick Neven; Hans Wildiers; Geert Maleux Journal: Radiol Oncol Date: 2020-01-21 Impact factor: 2.991